Recent News

• 09.12.2025 - FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
• 09.11.2025 - FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
• 09.10.2025 - FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
• 08.27.2025 - FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 07.31.2025 - FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 07.28.2025 - FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
• 07.11.2025 - FibroBiologics to Present at the Advanced Wound Care Summit USA
• 07.09.2025 - FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
• 07.07.2025 - FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
• 06.16.2025 - FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

Recent Filings

• 08.08.2025 - 8-K Current report
• 07.31.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.18.2025 - 8-K Current report
• 07.18.2025 - 8-K/A Current report
• 07.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.03.2025 - 8-K Current report
• 06.16.2025 - EX-99.1 EX-99.1
• 06.16.2025 - 8-K Current report
• 06.13.2025 - 8-K Current report